SCHEMBL30625217

SCHEMBL30625217

NNCC1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 12/20 0.69
CYP2D6 P10635 4/20 0.67
CYP2C9 P11712 4/20 0.67
SMN1; SMN2 Q16637 3/20 0.66
CYP2C19 P33261 1/20 0.66
NPC1 O15118 2/20 0.65
RAB9A P51151 2/20 0.65
CYP3A4 P08684 3/20 0.64
TPSAB1 Q15661 2/20 0.61
TPSD1 Q9BZJ3 2/20 0.61
TPSG1 Q9NRR2 2/20 0.61
F2 P00734 1/20 0.57
PLG P00747 1/20 0.57
PRSS1 P07477 1/20 0.57
PRSS2 P07478 1/20 0.57
PRSS3 P35030 1/20 0.57
HTT P42858 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30625242 0.92 GRIN2B (0.60) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL10153811 0.87 GRIN2B (0.69) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL4286977 0.87 GRIN2B (0.69) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL29532829 0.86 GRIN2B (0.67) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL1495904 0.86 GRIN2B (0.67) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL618588 0.85 SMN1; SMN2 (0.71) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL34466702 0.84 GRIN2B (0.62) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
Hydrochloric Acid SCHEMBL23301123 0.84 SMN1; SMN2 (0.69) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL696467 0.84 SMN1; SMN2 (0.69) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19
SCHEMBL5366902 0.84 TPSAB1 (0.72) GRIN2BCYP2D6CYP2C9SMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270213-A1 PI3Ka INHIBITORS PIKAVATION THERAPEUTICS, INC. 2025-08-28 US disclosed
CN-119654321-A PI3K alpha inhibitors 突触活化疗法股份有限公司 2025-03-18 CN disclosed
EP-4511373-A1 PI3K? INHIBITORS Synnovation Therapeutics, Inc. (US) 2025-02-26 EP disclosed
WO-2023205680-A1 PI3Kα INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270213-A1 PI3Ka INHIBITORS PIK3CA, PIK3C2A, PIK3R5 GRIN2B 2502/4885CYP2D6 4741/4885CYP2C9 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.